S100A16 is a Prognostic Marker for Lung Adenocarcinomas

Saito, Keita; Kobayashi, Makoto; Nagashio, Ryo; Ryuge, Shinichiro; Katono, Ken; Nakashima, Hiroyasu; Tsuchiya, Benio; Jiang, Shi Xu; Saegusa, Makoto; Satoh, Yukitoshi; Masuda, Noriyuki; Sato, Yuichi

doi:10.7314/apjcp.2015.16.16.7039

Cited by 31 publications

(32 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are no reports on the expression of S100A16 in cervical carcinoma. It has been reported that a high S100A16 expression level is correlated to poor prognosis in breast cancer and lung adenocarcinoma (27,28), whereas a low S100A16 expression level is correlated with reduced survival and poor tumor differentiation in oral squamous cell carcinoma (29). Further studies are needed to clarify the function of S100A16 and its clinical significance in the various cancer types.…”

Section: Discussionmentioning

confidence: 99%

S100A16 up‑regulates Oct4 and Nanog expression in cancer stem‑like cells of Yumoto human cervical carcinoma cells

et al. 2018

View full text Add to dashboard Cite

Abstract. Cancer stem-like cells (CSCs), which possess the ability to self-renewal and are multipotent, are regarded as the cause of tumor formation, recurrence, metastasis and drug resistance. It is necessary to understand the properties of CSCs in order to treat them effectively. It has been previously reported that S100 family proteins, which carry calcium-binding EF-hand motifs and are associated with tumorigenic processes, serve crucial roles in maintaining cancer stem-like properties. S100A16 is upregulated in various types of cancer, including bladder, lung and pancreatic. However, the roles of S100A16 in cancer cells, particularly CSCs, are not clear. The present study investigated the roles of S100A16 in CSCs using the sphere formation assay of Yumoto cells, which are a human cervical carcinoma cell line. The mRNA expression levels were evaluated by reverse transcription-polymerase chain reaction and the protein expression levels were detected by western blot analysis. Following the sphere formation of Yumoto cells, the mRNA and protein expression level of Oct4, Nanog and S100A16 were increased compared with the control cells. Following transfection with S100A16 small interfering RNA (siRNA), the mRNA and protein expression of Oct4 and Nanog were decreased and the spheroid size was significantly decreased in the sphere formation of Yumoto cells compared with control siRNA treated cells. There was no change in the p53 mRNA expression level, whereas the p53 protein expression level, which was decreased by the sphere formation, was recovered by S100A16 knockdown. In addition, the protein expression levels of Oct4 and Nanog, which were increased in the sphere formation, were decreased by the proteasome inhibitor lactacystin. No differences were observed in the S100A16 protein expression between the presence or absence of lactacystin. These results suggest that S100A16 serves an important role in the CSCs of human cervical carcinoma and is a positive regulator of Oct4 and Nanog.

show abstract

Section: Discussionmentioning

confidence: 99%

S100A16 up‑regulates Oct4 and Nanog expression in cancer stem‑like cells of Yumoto human cervical carcinoma cells

et al. 2018

View full text Add to dashboard Cite

show abstract

“…For example, the co‐expression of S100A14 and S100A16 correlated with a poor prognosis in human breast cancer and promoted the invasive activity of breast cancer cells via an interaction with cytoskeletal dynamics (Sapkota et al , ). High S100A16 expression was found to be significantly associated with a poor prognosis in lung, prostate and breast cancers (Saito et al , ). Conversely, recent studies reported that the decreased expression of S100A16 predicts poor prognosis in oral squamous cell carcinoma (OSCC) and colorectal cancer (Sapkota et al , ; Sun et al , ).…”

mentioning

confidence: 99%

S100A16suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukaemia

Zhang

et al. 2019

Br J Haematol

View full text Add to dashboard Cite

Summary Refinement of risk stratification in Philadelphia chromosome (Ph)‐negative B‐cell acute lymphoblastic leukaemia (ALL) might aid the identification of patients who are likely to relapse. Abnormal S100 calcium binding protein A16 (S100A16) has been implicated in various cancers, but its function remains unclear. We found S100A16 transcript levels were higher in 130 adults with newly‐diagnosed Ph‐negative B‐cell ALL compared with 33 healthy controls. In 115 of 130 patients who achieved first complete remission, those with high S100A16 transcript levels displayed a lower 3‐year cumulative incidence of relapse (CIR; 34% [21, 47%] vs. 40% [48, 72%]; P = 0·012) and higher 3‐year relapse‐free survival (RFS; 65% [53, 78%] vs. 35% [23, 46%]; P = 0·012), especially when receiving chemotherapy only. In multivariate analysis a low S100A16 transcript level was independently‐associated with a higher CIR (Hazard ratio [HR] = 3·74 [1·01–13·82]; P = 0·048) and inferior RFS (HR = 5·78 [1·91, 17·84]; P < 0·001). Function analysis indicated that knockdown of S100A16 promoted proliferation and anti‐apoptosis and reduced chemosensitivity. S100A16 over‐expression revealed an opposite trend, especially in a xeno‐transplant mouse model. Western blotting analysis showed upregulation of PI3K/AKT and ERK1/2 in S100A16‐knockdown and S100A16‐overexpression B‐cell ALL cell lines respectively. Inhibition assays suggested these two signalling pathways participated in the S100A16‐mediated proliferation and survival effects in B‐cell ALL cell lines. Trial Registration: Registered in the Chinese Clinical Trial Registry [ChiCTR‐OCH‐10000940]; http://www.chictr.org.cn.

show abstract

“…We previously reported that S100A10 and S100A16 are expressed in a subset of lung adenocarcinoma [10,11]. In the present study, 164 patients were enrolled.…”

Section: Evaluation Of Relationship Between S100a14 Expression and Otmentioning

confidence: 99%

“…We evaluated the relationship between S100A14 expression and S100A10 or S100A16 expression in the 164 patients. The procedures for immunohistochemical staining and evaluation of staining for S100A10 and S100A16 were described in our previous study [10,11].…”

Section: Evaluation Of Relationship Between S100a14 Expression and Otmentioning

confidence: 99%

“…Moreover, expression of the S100 protein family is detected in many human cancers and has been correlated with a poorer prognosis [9]. In lung cancer, we previously reported that S100A10 and S100A16 are expressed in a subset of lung adenocarcinoma; their expression is correlated with a poorer prognosis, especially S100A16 expression which is an independent prognostic factor in complete resected lung adenocarcinoma [10,11]. S100A14 was recently identified as a new member of the S100 protein family by analyzing a human metastatic small cell lung carcinoma cell line subtraction cDNA library and is up-regulated in several tumors such as ovarian, breast, and uterine, but down-regulated in kidney, rectal, and colon tumors [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological Significance of S100A14 Expression in Lung Adenocarcinoma

Katono

Sato

Kobayashi³

et al. 2017

Oncol Res Treat

Self Cite

View full text Add to dashboard Cite

Background: Several studies have reported that S100A14 plays important roles during different steps of the tumorigenic process and tumor progression of several types of cancer. The aim of the present study was to investigate the clinicopathological and prognostic significance and functional roles of S100A14 in lung adenocarcinoma. Patients and Methods: S100A14 expression was immunohistochemically studied in 166 consecutive resected lung adenocarcinomas, and its correlation with clinicopathological parameters was evaluated. Functional roles of S100A14 in lung adenocarcinoma were investigated based on invasion and migration assays on a small interfering (si)RNA-treated lung adenocarcinoma cell line. Results: S100A14 expression was detected in 82 of the 166 (49.4%) lung adenocarcinomas. S100A14 expression was significantly correlated with sex, poorer tumor differentiation, higher disease stages, larger tumor size, lymph node metastasis, intratumoral vascular invasion, intratumoral lymphatic invasion, pleural invasion, and poorer prognosis. Invasion and wound healing assays showed that S100A14 siRNA knockdown cells had significantly decreased invasion and migration abilities compared with siRNA control cells. Conclusion: S100A14 is expressed in a subset of lung adenocarcinoma, and its expression is related to certain clinicopathological parameters. Furthermore, S100A14 expression was strongly correlated with migration and invasion in lung adenocarcinoma cells.

show abstract

S100A16 is a Prognostic Marker for Lung Adenocarcinomas

Cited by 31 publications

References 20 publications

S100A16 up‑regulates Oct4 and Nanog expression in cancer stem‑like cells of Yumoto human cervical carcinoma cells

S100A16 up‑regulates Oct4 and Nanog expression in cancer stem‑like cells of Yumoto human cervical carcinoma cells

S100A16suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukaemia

Clinicopathological Significance of S100A14 Expression in Lung Adenocarcinoma

Contact Info

Product

Resources

About